Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir (JNJ-53718678) in children with RSV
NCT03656510Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial of rilematovir in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Respiratory Syncytial Virus (RSV) Viral Load Area Under Curve (AUC) From Immediately Prior to First Dose Through Day 5. Started Nov 2018; status: terminated.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03656510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656510.